Candel Therapeutics (CADL) Projected to Post Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is anticipated to issue its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Candel Therapeutics Trading Up 0.8%

CADL stock opened at $4.95 on Thursday. The company has a quick ratio of 8.25, a current ratio of 8.25 and a debt-to-equity ratio of 0.01. Candel Therapeutics has a twelve month low of $4.25 and a twelve month high of $9.08. The company has a market cap of $271.76 million, a P/E ratio of -8.68 and a beta of -0.91. The business has a fifty day moving average of $5.70 and a 200-day moving average of $5.47.

Insider Activity

In related news, Director Paul B. Manning acquired 550,458 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the acquisition, the director directly owned 2,763,527 shares in the company, valued at approximately $15,061,222.15. The trade was a 24.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 16.60% of the company’s stock.

Hedge Funds Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Candel Therapeutics by 12.3% in the third quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock valued at $10,236,000 after buying an additional 219,563 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Candel Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock valued at $5,524,000 after purchasing an additional 49,315 shares in the last quarter. State Street Corp boosted its stake in shares of Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock valued at $4,476,000 after purchasing an additional 103,452 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Candel Therapeutics during the 3rd quarter valued at approximately $697,000. Finally, Wells Fargo & Company MN increased its position in Candel Therapeutics by 180.9% during the 4th quarter. Wells Fargo & Company MN now owns 73,899 shares of the company’s stock worth $418,000 after purchasing an additional 47,588 shares in the last quarter. 13.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Citigroup dropped their target price on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Zacks Research downgraded Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Stephens reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Candel Therapeutics in a research note on Monday, December 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.